{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:26:55Z","timestamp":1770352015949,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jdsjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jdermsci.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T06:32:16Z","timestamp":1705818736000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice"],"prefix":"10.1016","volume":"113","author":[{"given":"Antti","family":"N\u00e4tynki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Kokkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi","family":"Tuusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Ohlmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisa","family":"Tasanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2024.01.003_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib3","article-title":"Emerging role of dipeptidyl peptidase-4 in autoimmune disease","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent advances in understanding pemphigus and bullous pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib5","doi-asserted-by":"crossref","first-page":"12233","DOI":"10.3390\/ijms222212233","article-title":"BP180\/collagen XVII: a molecular view","volume":"22","author":"Tuusa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish Nationwide Registry Study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib9","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc18-0210","article-title":"Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database","volume":"41","author":"Arai","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdermsci.2024.01.003_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jdi.14004","article-title":"Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase\u20104 inhibitors: a population\u2010based cohort study using Japanese Latter\u2010Stage Elderly Healthcare Database","volume":"14","author":"Harano","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03192-8","article-title":"Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin","volume":"19","author":"Chouchane","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2165\/11591400-000000000-00000","article-title":"Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences","volume":"71","author":"Baetta","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jdermsci.2024.01.003_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2015.00387","article-title":"The dipeptidyl peptidase family, prolyl oligopeptidase and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis","volume":"6","author":"Waumans","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jcmm.13402","article-title":"Expression of CPPED1 in human trophoblasts is associated with timing of term birth","volume":"22","author":"Haapalainen","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib16","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jid.2020.10.020","article-title":"Galectin-1 expression in CD8+ T lymphocytes controls inflammation in contact hypersensitivity","volume":"141","author":"Castillo-Gonz\u00e1lez","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10753-021-01608-7","article-title":"Expression pattern and immunoregulatory roles of galectin-1 and galectin-3 in atopic dermatitis and psoriasis","volume":"45","author":"Corr\u00eaa","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.jdermsci.2024.01.003_bib19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00109-017-1566-9","article-title":"Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis","volume":"95","author":"Corr\u00eaa","year":"2017","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1248\/bpb.b16-01011","article-title":"Pathophysiological roles of ezrin\/radixin\/moesin proteins","volume":"40","author":"Kawaguchi","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1083\/jcb.201304052","article-title":"The actin-binding ERM protein Moesin binds to and stabilizes microtubules at the cell cortex","volume":"202","author":"Solinet","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib22","first-page":"68","article-title":"Clinical safety and tolerability of vildagliptin - insights from randomised trials, observational studies and post-marketing surveillance","volume":"13","author":"Mathieu","year":"2017","journal-title":"Eur. Endocrinol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-021-00625-4","article-title":"DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020","volume":"22","author":"Jedlowski","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case\u2013noncase study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib26","first-page":"1137","article-title":"HBV triggers APOBEC2 expression through miR-122 regulation and affects the proliferation of liver cancer cells","volume":"55","author":"Li","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib27","doi-asserted-by":"crossref","first-page":"28924","DOI":"10.1074\/jbc.M114.603043","article-title":"Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (apobec2), mediate its effect on zebrafish retina regeneration","volume":"289","author":"Powell","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.biocel.2017.02.005","article-title":"APOBEC2 negatively regulates myoblast differentiation in muscle regeneration","volume":"85","author":"Ohtsubo","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrm2866","article-title":"Organizing the cell cortex: the role of ERM proteins","volume":"11","author":"Fehon","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.604206","article-title":"Actin remodeling defects leading to autoinflammation and immune dysregulation","volume":"11","author":"Papa","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1152\/ajpcell.00075.2010","article-title":"Actin reorganization contributes to loss of cell adhesion in pemphigus vulgaris","volume":"299","author":"Gliem","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib32","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1096\/fj.201500160R","article-title":"A hemidesmosomal protein regulates actin dynamics and traction forces in motile keratinocytes","volume":"30","author":"Hiroyasu","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib33","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.4049\/jimmunol.1701172","article-title":"Galectin-1: A Jack-of-All-Trades in the resolution of acute and chronic inflammation","volume":"199","author":"Sundblad","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/ni1482","article-title":"Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death","volume":"8","author":"Toscano","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0192623313516828","article-title":"Vascular origin of vildagliptin-induced skin effects in cynomolgus monkeys:pathomechanistic role of peripheral sympathetic system and neuropeptide Y","volume":"42","author":"Hoffmann","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/JME-12-0039","article-title":"DPP4 inhibitor vildagliptin preserves \u03b2-cell mass through amelioration of endoplasmic reticulum stress in C\/EBPB transgenic mice","volume":"49","author":"Shimizu","year":"2012","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/jnc.13439","article-title":"The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes","volume":"136","author":"Tsuboi","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40261-022-01242-7","article-title":"Comparison of adverse events occurred during administration of dipeptidyl peptidase-4 inhibitor in patients with diabetes using FDA adverse event reporting system","volume":"43","author":"Ogura","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","article-title":"Risk factors and cardiovascular disease prevention the role of inflammation in diabetes: current concepts and future perspectives","volume":"14","author":"Tsalamandris","year":"2019","journal-title":"Eur. Cardiol. Rev."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib40","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jid.2020.11.006","article-title":"Inflammaging and the skin","volume":"141","author":"Pilkington","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jdermsci.2024.01.003_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-016-0176-y","article-title":"Skin disorders in diabetes mellitus: an epidemiology and physiopathology review","volume":"8","author":"De Macedo","year":"2016","journal-title":"Diabetol. Metab. Syndr."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181124000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181124000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T10:21:38Z","timestamp":1729160498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181124000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0923181124000112"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2024.01.003","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}